788 related articles for article (PubMed ID: 27729627)
1. Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B.
Lee J; Yoo SH; Sohn W; Kim HW; Choi YS; Won JH; Heo JY; Park SJ; Park YM
Clin Mol Hepatol; 2016 Sep; 22(3):339-349. PubMed ID: 27729627
[TBL] [Abstract][Full Text] [Related]
2. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
Sohn W; Cho JY; Kim JH; Lee JI; Kim HJ; Woo MA; Jung SH; Paik YH
Clin Mol Hepatol; 2017 Jun; 23(2):170-178. PubMed ID: 28506056
[TBL] [Abstract][Full Text] [Related]
3. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
4. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B.
Kim BG; Park NH; Lee SB; Jeon S; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
Liver Int; 2018 Dec; 38(12):2269-2276. PubMed ID: 30052303
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Nikolopoulou G; Raptopoulou-Gigi M; Gogos C; Vafiadis-Zouboulis I; Karamanolis D; Chouta A; Ilias A; Drakoulis C; Mimidis K; Ketikoglou I; Manesis E; Mela M; Hatzis G; Dalekos GN;
J Viral Hepat; 2015 Feb; 22(2):120-7. PubMed ID: 25040685
[TBL] [Abstract][Full Text] [Related]
6. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870
[TBL] [Abstract][Full Text] [Related]
7. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.
Wong GL; Chan HL; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Lai JW; Lo AO; Chan HY; Wong VW
Hepatology; 2013 Nov; 58(5):1537-47. PubMed ID: 23389810
[TBL] [Abstract][Full Text] [Related]
8. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
[TBL] [Abstract][Full Text] [Related]
9. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
[TBL] [Abstract][Full Text] [Related]
10. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
Park YH; Kim BK; Kim JK; Kim HC; Kim DY; Park JY; Han KH; Kim SU; Shin SH; Hahn KY; Ahn SH
J Gastroenterol Hepatol; 2014 May; 29(5):1005-11. PubMed ID: 24325579
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Sypsa V; Dalekos GN; Yurdaydin C; Van Boemmel F; Buti M; Calleja JL; Chi H; Goulis J; Manolakopoulos S; Loglio A; Voulgaris T; Gatselis N; Keskin O; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Idilman R; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Jun; 72(6):1088-1096. PubMed ID: 31981727
[TBL] [Abstract][Full Text] [Related]
13. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.
Lim YS; Han S; Heo NY; Shim JH; Lee HC; Suh DJ
Gastroenterology; 2014 Jul; 147(1):152-61. PubMed ID: 24583062
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment.
Wong GL; Chan HL; Chan HY; Tse PC; Tse YK; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Wong VW
Gastroenterology; 2013 May; 144(5):933-44. PubMed ID: 23415803
[TBL] [Abstract][Full Text] [Related]
15. Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy.
Fan R; Niu J; Ma H; Xie Q; Cheng J; Rao H; Dou X; Xie J; Zhao W; Peng J; Gao Z; Gao H; Chen X; Chen J; Li Q; Tang H; Zhang Z; Ren H; Cheng M; Liang X; Zhu C; Wei L; Jia J; Sun J; Hou J;
Aliment Pharmacol Ther; 2021 Aug; 54(3):329-338. PubMed ID: 34157146
[TBL] [Abstract][Full Text] [Related]
16. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
Kim GA; Han S; Kim HD; An J; Lim YS
J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
[TBL] [Abstract][Full Text] [Related]
17. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
[TBL] [Abstract][Full Text] [Related]
18. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
[TBL] [Abstract][Full Text] [Related]
19. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.
Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
J Gastroenterol Hepatol; 2019 Feb; 34(2):442-449. PubMed ID: 29968933
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs.
Tsai MC; Chen CH; Hu TH; Lu SN; Lee CM; Wang JH; Hung CH
J Formos Med Assoc; 2017 Jul; 116(7):512-521. PubMed ID: 27720344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
